Poor quality medicines are a real and urgent threat that could undermine decades of successful efforts to combat HIV/AIDS, malaria and tuberculosis, according to the editors of a new collection of journal articles.
Poor quality antimalarial drugs lead to drug resistance and inadequate treatment that pose an urgent threat to vulnerable populations, according to a Fogarty study.
Fogarty and NIAID convened drug-resistant malaria experts to examine the problem, identify possible approaches, spark collaborations and spur the field to take action.
An international collaboration that includes NIAID uncovered a mutation in the malaria parasite in Cambodia that enables it to survive artemisinin, the most potent antimalarial drug available.